A Phase 2, Single dose, Open-Label, Exploratory Study to Investigate the Safety and Efficacy of OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules

On Target Laboratories, LLC0 个研究点目标入组 110 人开始时间: 2017年10月18日最近更新: 2017年11月6日

适应症

试验速览

暂无简介。

•1. Male and Female patients 18 years of age and older
•2. Confirmed diagnosis of adenocarcinoma lung cancer
•3. Have a primary diagnosis, or at high clinical suspicion, of lung nodule(s) warranting surgery based on CT and/or PET imaging
•4. Who are scheduled to undergo endoscopic or thoracic surgery
•5. A negative serum pregnancy test at Screening followed by a negative urine pregnancy test on the day of surgery or day of admission for female patients of childbearing potential
•6. Female patients of childbearing potential or less than 2 years postmenopausal agree to use an acceptable form of contraception from the time of signing informed consent until 30 days after study completion
•7. Ability to understand the requirements of the study, provide written informed consent and authorization of use and disclosure of protected health information, and agree to abide by the study restrictions and to return for the required assessments
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 10
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•1. Previous exposure to OTL38
•2. Known FR-negative lung nodules
•3. Any medical condition that in the opinion of the investigators could potentially jeopardize the safety of the patient
•4. History of anaphylactic reactions
•5. History of allergy to any of the components of OTL38, including folic acid
•6. Pregnancy, or positive pregnancy test
•7. Clinically significant abnormalities on electrocardiogram (ECG) at screening.
•8. Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
•9. Impaired renal function defined as eGFR< 50 mL/min/1.73m2
•10. Impaired liver function defined as values > 3x the upper limit of normal (ULN) for alanine aminotransferase (ALT) or aspartate aminotransferase (AST), alkaline phosphatase (ALP), or total bilirubin.
•11. Received an investigational agent in another investigational drug or vaccine trial within 30 days prior to surgery
•12. Known sensitivity to fluorescent light

发起方